Pediatric AIDS caused by human immunodeficiency virus type 1 (HIV-1) remains one of the leading worldwide causes of childhood morbidity and mortality. HIV-1 proteins, such as Tat and gp120, are believed to play a crucial role in the neurotoxicity of pediatric HIV-1 infection. Detrimental effects on development, behavior, and neuroanatomy follow neonatal exposure to the HIV-1 viral toxins Tat 1-72 and gp120. The present study investigated the neurobehavioral effects induced by the HIV-1 neurotoxic protein Tat 1-86 , which encodes the first and second exons of the Tat protein. In addition, the potential effects of HIV-1 toxic proteins Tat 1-86 and gp120 on inflammatory pathways were examined in neonatal brains. Vehicle, 25 g Tat 1-86 or 100 ng gp120 was injected into the hippocampus of male Sprague-Dawley pups on postnatal day 1 (PD1). Tat 1-86 induced developmental neurotoxic effects, as witnessed by delays in eye opening, delays in early reflex development and alterations in prepulse inhibition (PPI) and between-session habituation of locomotor activity. Overall, the neurotoxic profile of Tat 1-86 appeared more profound in the developing nervous system in vivo relative to that seen with the first exon encoded Tat 1-72 (Fitting et al., 2008b), as noted on measures of eye opening, righting reflex, and PPI. Neither the direct PD1 CNS injection of the viral HIV-1 protein variant Tat 1-86 , nor the HIV-1 envelope protein gp120, at doses sufficient to induce neurotoxicity, necessarily induced significant expression of the inflammatory cytokine IL-1␤ or inflammatory factors NF-␤ and I-␤. The findings agree well with clinical observations that indicate delays in developmental milestones of pediatric HIV-1 patients, and suggest that activation of inflammatory pathways is not an obligatory response to viral protein-induced neurotoxicity that is detectable with behavioral assessments. Moreover, the amino acids encoded by the second tat exon may have unique actions on the developing hippocampus.
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Introduction
Pediatric human immunodeficiency virus type 1 (HIV-1) infection is a matter of global concern, though it is not equally distributed around the world. As of 2012, ∼3.3 million children (under age 15) have been reported to live with HIV-1, with most of these children living in Sub-Saharan Africa (∼2.9 million) and less than 1% living in Northern America and Western and Central Europe (UNAIDS, 2013) . With the introduction of antiretroviral therapies given to HIV-1 infected women during pregnancy, the transmission rate of HIV-1 has decreased dramatically (Suksomboon et al., 2007; Volmink et al., 2007) , although in developing countries, the motherto-child transmission rate of HIV-1 remains very high, ranging from 23% to 34%, with an estimated 260,000 children newly infected in 2012 (UNAIDS, 2013) . Because the developing brains of infants and children are extremely vulnerable to this debilitating disease (Mintz, 1994) , pediatric HIV-1 is of special interest. The transition of HIV-1 from an acute, lethal disease to a subacute, chronic disease has major implications for the neurocognitive development of children. In the era of combination antiretroviral therapy (cART), vertically acquired HIV-1 infected children that survive to http://dx.doi.org/10.1016/j.ijdevneu.2014.09.004 0736-5748/© 2014 ISDN. Published by Elsevier Ltd. All rights reserved.
